Medicis Announces Notice of Allowance for SOLODYN(R) 90mg
SCOTTSDALE, Ariz., April 3, 2009 (GLOBE NEWSWIRE) -- Medicis (NYSE:MRX) today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for Medicis' United States patent application directed to the use of SOLODYN(R) in 90mg tablet form. For the week ending March 20, 2009, the 90mg strength represented over 60% of total SOLODYN(R) prescriptions.(1) (Source: Medical News (via PRIMEZONE))
1 in 5 Americans Will Get Skin Cancer. Will It Be You?
Melanoma, the deadliest form, increasingly strikes younger adults. Here’s how to cut your risk. (Source: U.S. News - Health)div id=medwormpbiMedWorm Sponsor Message:/i/b Have a look at a href=http://www.thepsychologydaily.comThe Psychology Daily/a, the new psychology portal powered by MedWorm, with all the latest psychology news and research updated daily./p/div